The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Better Statistical Methods To Discover Host Genetic Factors In Symptom Response To SARS-CoV-2 Infection
Funder
National Health and Medical Research Council
Funding Amount
$290,137.00
Summary
The COVID-19 pandemic has infected >5 million people worldwide. While the majority of infected individuals recover within a few weeks of infection, others develop severe forms, that in some cases prove fatal. To date, the causes of differences in symptom response are unknown. In this proposal, we seek to discover genetic factors that can contribute to explaining these differences. Our findings have the potential to inform the design and analysis of clinical trials for vaccines and treatments.
Epigenetic Biomarker Discovery For Cardiovascular Disease Risk Stratification Of Women Following Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$1,275,101.00
Summary
Those women whom have suffered from severe complications during pregnancy have an increased risk of developing heart disease. This increased risk may be due to epigenetic changes during pregnancy that alter the expression of specific genes. These epigenetic changes persist after birth and increase heart disease risk for these women. This project seeks to evaluate those epigenetic changes associated with severe pregnancy complications predicting heart disease in a large group of Australian women.
Determining The Molecular Basis Of Therapy Resistance Conferred By Genetic Lesions In The Tumour Protein TP53 In Haematological Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$885,183.00
Summary
Blood cancers that have genetic lesions in a tumour suppressor protein called TP53 respond poorly to therapy. Curing these patients is extremely challenging and new therapeutic strategies are desperately needed. Here, we aim to uncover the molecular mechanisms of drug resistance caused by loss of TP53 function and rationally design new therapies that may be curative. To do this, our team of leading scientists and clinicians will study patient samples and pre-clinical models of blood cancer.